LMB040

LMB040 is a **preclinical light-activated oncolytic peptide** being developed by **Lumobiotics** for **hepatocellular adenocarcinoma**. It is a photoswitchable peptidic therapeutic designed to remain comparatively inactive systemically and to become cytotoxic after **red-light irradiation at 650 nm**, enabling localized activation at the tumor site. Its reported mechanism is disruption of the **cancer cell membrane**, producing oncolytic activity with the goal of improving spatiotemporal selectivity and limiting off-tumor toxicity in healthy tissues. Publicly available company materials place LMB040 in **preclinical** development, and broader Lumobiotics materials indicate this platform has been evaluated in vivo in hepatocellular carcinoma models.